-
-
Recognizing that patients and consumers are the key players in healthcare, all employees are recommended to spend 1% of their working hours with patients
-
February 22, 2021
-
February 22, 2021
-
February 15, 2021
-
February 3, 2021
-
February 1, 2021
EISAI TO LAUNCH PARKINSON’S DISEASE TREATMENT EQUFINA® IN SOUTH KOREA
-
February 24, 2021
-
February 4, 2021
-
February 3, 2021
IR “Third Quarter Financial Report for the Fiscal Year Ending March 31, 2021”
-
November 26, 2020
-
December 10, 2020
Notice of Emergence of Employees Infected with the Novel Coronavirus at the Bogor Plant in Indonesia
-
December 3, 2020
EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT FIFTH ANNUAL WELFARE INDEX PMI* IN ITALY
-
October 28, 2020
-
August 4, 2020
Notice of Emergence of Employees Infected with the Novel Coronavirus at Eisai’s Vizag Plant in India
-
February 14, 2020
EISAI TO VOLUNTARILY WITHDRAW ANTIOBESITY AGENT BELVIQ® / BELVIQ XR® IN THE U.S.
-
Annual Financial Results for the Fiscal Year Ended March 31, 2021
-
Our Response to the Novel Coronavirus Infection
-
Florence Nightingale Virtual Gallery
-
#ThisIsMBC Elements Campaign Showcases Powerful Portraits of Patients Living with Metastatic Breast Cancer and Their Caregivers Sharing Their Journeys to Inspire Others
Eisai's hhc Philosophy
Sustainability
28 countries 2.01 billion tablets
Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of December 2020)
Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries
